- Home
- GITS vs GRI Comparison
GITS vs GRI Comparison
Compare GITS & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- GRI
- Stock Information
- Founded
- GITS 2018
- GRI 2018
- Country
- GITS South Korea
- GRI United States
- Employees
- GITS N/A
- GRI N/A
- Industry
- GITS
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- GRI Health Care
- Exchange
- GITS Nasdaq
- GRI Nasdaq
- Market Cap
- GITS 4.1M
- GRI 3.6M
- IPO Year
- GITS N/A
- GRI N/A
- Fundamental
- Price
- GITS $2.18
- GRI $1.39
- Analyst Decision
- GITS
- GRI Strong Buy
- Analyst Count
- GITS 0
- GRI 2
- Target Price
- GITS N/A
- GRI $22.00
- AVG Volume (30 Days)
- GITS 27.5K
- GRI 89.3K
- Earning Date
- GITS 08-15-2025
- GRI 08-14-2025
- Dividend Yield
- GITS N/A
- GRI N/A
- EPS Growth
- GITS N/A
- GRI N/A
- EPS
- GITS N/A
- GRI N/A
- Revenue
- GITS $29.00
- GRI N/A
- Revenue This Year
- GITS N/A
- GRI N/A
- Revenue Next Year
- GITS N/A
- GRI N/A
- P/E Ratio
- GITS N/A
- GRI N/A
- Revenue Growth
- GITS N/A
- GRI N/A
- 52 Week Low
- GITS $0.87
- GRI $1.10
- 52 Week High
- GITS $9.78
- GRI $30.43
- Technical
- Relative Strength Index (RSI)
- GITS 46.10
- GRI 45.82
- Support Level
- GITS $2.12
- GRI $1.33
- Resistance Level
- GITS $2.34
- GRI $1.45
- Average True Range (ATR)
- GITS 0.16
- GRI 0.09
- MACD
- GITS -0.00
- GRI 0.01
- Stochastic Oscillator
- GITS 35.00
- GRI 55.00
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.